Br Med J. 1976 Feb 14;1(6006):361-4.
A long-term double-blind trial of sodium cromoglycate (SCG) with and without isoprenaline, with a placebo control, was undertaken in Edinburgh to a similar design as a previously reported trial in London. The results from the two centres were compared and combined. In Edinburgh 41 patients were studied for 36 weeks and 40 for 52 weeks and in the combined series 121 were studied for 36 weeks and 114 for 52 weeks. In the second year 14 patients were followed-up in Edinburgh and 27 in London. The two SCG regimens were superior overall to placebo both in the Edinburgh and London patients. SCG was effective in similar proportions of patients with extrinsic and intrinsic asthma. In the second year the effectiveness of SCG was further tested by randomly allocating half the patients to a placebo. Some patients derived a continuing benefit from SCG, but its continued use did not appear to be necessary for others, whose progress on placebo was satisfactory.
在爱丁堡进行了一项色甘酸钠（SCG）的长期双盲试验，该试验设有使用和不使用异丙肾上腺素的组，并设有安慰剂对照，其设计与之前在伦敦报道的试验类似。对两个中心的结果进行了比较和合并。在爱丁堡，41名患者接受了36周的研究，40名患者接受了52周的研究；在合并后的系列中，121名患者接受了36周的研究，114名患者接受了52周的研究。在第二年，爱丁堡有14名患者、伦敦有27名患者接受了随访。两种SCG治疗方案在爱丁堡和伦敦的患者中总体上均优于安慰剂。SCG对外源性和内源性哮喘患者的有效比例相似。在第二年，通过将一半患者随机分配到安慰剂组，进一步测试了SCG的有效性。一些患者从SCG中持续获益，但对另一些患者来说，持续使用SCG似乎并非必要，他们使用安慰剂的进展情况令人满意。
